Skip to Main Content

Paper Details

Establishing a Case for Anti-complement Therapy in Membranous Nephropathy.
Kidney Int Rep
11
2020
C1q, C3, C4, C5, C5a, C5b-9, C6, C7, C8, C9, CR1, FH, FH-related protein 2, FHR2, IgG, MAC, MN, Membranous Nephropathy, Membranous nephropathy, autoimmune disease, clusterin, complement proteins, complement receptor type 1, end-stage kidney disease, factor H, human, lectin, nephrotic syndrome, pMN, primary (p) MN cohorts, vitronectin
Author NameAffiliation
Isabelle AyoubThe Ohio State University Wexner Medical Center
Samir M ParikhThe Ohio State University Wexner Medical Center
Samir M ParikhThe Ohio State University Wexner Medical Center
Salem AlmaaniThe Ohio State University Wexner Medical Center
Lianbo YuCenter for Biostatistics, The Ohio State University Wexner Medical Center
Brad H RovinThe Ohio State University Wexner Medical Center
Brad H RovinThe Ohio State University Wexner Medical Center
  • 1 - 7

Datasets

Release 1.2